GET DAILY SIGNALSBurning Rock Biotech (BNR) Shares Drop -37% in 30 Days After September Rally
Key Takeaways
- Burning Rock Biotech (BNR) shares fell roughly 37% over the past 30 days, from about $16.25 to around $10.19, after a sharp rally briefly pushed the stock above $18 in late September.
- The decline reflects profit-taking and a valuation reset following a September surge tied to regulatory milestones, personalized MRD kit designations, and a global licensing partnership with Myriad Genetics (MYGN).
- Over the broader three-month window, BNR remains approximately 15% higher, underscoring the stock's high volatility rather than a single-direction trend.
- Second-quarter 2026 results, reported on September 10, showed total revenue of RMB134.7 million (US$19.9 million), down 9.3% year over year, alongside a widened net loss of RMB18.4 million.
- The company continues to advance a pipeline of next-generation sequencing (NGS) diagnostics, including liquid biopsy and personalized minimal residual disease (MRD) tests under priority review in China.
Company Snapshot: Burning Rock Biotech (BNR)
Burning Rock Biotech Limited is a China-based precision oncology company that applies next-generation sequencing (NGS) technology to cancer diagnostics. Founded in 2014 and headquartered in Guangzhou, the company operates across three segments: central laboratory testing, in-hospital testing, and pharmaceutical research and development services. Its portfolio includes tissue- and liquid-biopsy-based therapy selection tests such as OncoScreen Plus and OncoCompass Plus, along with minimal residual disease (MRD) monitoring and companion diagnostic development for global drugmakers.
The company has established itself as a leading NGS-based diagnostics provider in China, supported by CAP-accredited and CLIA-certified laboratories and collaborations with more than 150 pharmaceutical companies. Investors follow BNR for its regulatory pipeline, expanding in-hospital testing footprint, and progress toward profitability, even as the business remains unprofitable and exposed to the volatile Chinese healthcare market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BNR has fallen approximately 37%, declining from a closing price of about $16.25 in early October to roughly $10.19. The pullback marked a sharp reversal after the stock had rallied from roughly $9.25 at the start of September to a late-September closing high near $18.94, meaning the shares roughly doubled before giving back a substantial portion of those gains.
Over the last quarter, the picture is different. From an early-August level near $8.84, BNR is still up approximately 15%, reflecting the steep September climb that preceded October's correction. The gap between the 30-day decline and the positive quarterly reading highlights a highly volatile, momentum-driven trading pattern rather than a stable directional trend. BNR's 52-week range of roughly $6.79 to $41.72 further illustrates this volatility.
What Drove the Recent 30-Day Decline
The recent 30-day decline was primarily a correction of an unusually rapid rally rather than a response to a single negative corporate event. After more than doubling in September, the stock became susceptible to profit-taking, particularly as independent valuation analyses flagged the shares as trading well above estimated intrinsic value at their September peak. The October pullback brought the stock back toward its pre-rally levels, with several sessions showing double-digit percentage declines on elevated volume.
The retreat occurred against a backdrop of mixed fundamentals. Second-quarter 2026 results showed a 9.3% year-over-year revenue decline to RMB134.7 million and a widened net loss of RMB18.4 million, even as in-hospital revenue rose 7.4% year over year and management emphasized a sequential recovery. Those results, combined with the stock's extended valuation, contributed to the corrective price action.
Quarterly Drivers and Regulatory Catalysts
The broader three-month trend was defined by a powerful September rally followed by an October correction. The rally was supported by a series of regulatory and partnership catalysts. In July 2026, the company announced a global technology licensing collaboration with Myriad Genetics to expand homologous recombination deficiency (HRD) testing worldwide. In August and September, Burning Rock's CanCatch Custom Kit and CanCatch Custom Kit (cPAS) entered China's Special Review Procedure for Innovative Medical Devices, and on September 24 a circulating tumor DNA multi-gene mutation detection kit entered the NMPA's priority review pathway.
These milestones drove substantial buying interest and elevated volume through late September. The subsequent pullback largely unwound the speculative portion of those gains, leaving the stock moderately higher over the full quarter as investors weighed the regulatory progress against still-negative earnings and valuation concerns. From what I see, this pattern is typical for smaller biotech names reacting to news flow.
Key Factors to Watch Going Forward
Several factors are likely to shape BNR's outlook. Regulatory progress remains central, including potential approvals for its liquid biopsy and MRD kits currently under priority review, as well as the commercialization of its OncoScreen BCMatch breast cancer companion diagnostic. Investors should also monitor in-hospital testing adoption, pharmaceutical R&D services revenue, and whether the company sustains its recent operating-cost discipline and moves toward breakeven or positive cash flow.
Macroeconomic and sector risks include policy shifts affecting China's healthcare and diagnostics market, reimbursement changes, and broader sentiment toward China-listed equities. Competitive pressures in the NGS diagnostics space and foreign-exchange movements between the renminbi and U.S. dollar may also influence reported results. As always, these factors present both opportunities and risks rather than guarantees of any specific price outcome. I’m watching this closely for any updates on the priority review timelines.
Integrating AI Tools Into My Research Process
When analyzing volatile names like BNR, I often turn to Tickeron’s Trending AI Robots to get a data-driven view alongside fundamentals. The platform highlights top-performing bots with different strategies and timeframes, which can offer useful context on momentum or trend signals without replacing traditional analysis. It’s a practical way to cross-check ideas in fast-moving sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BNR sees MACD Histogram crosses below signal line
BNR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 44 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BNR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BNR as a result. In 75 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
BNR moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNR crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BNR entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNR advanced for three days, in 193 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BNR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.209) is normal, around the industry mean (65.853). P/E Ratio (-0.940) is within average values for comparable stocks, (2.707). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.741) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. BNR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the investment of medical fields and specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology
Industry MedicalSpecialties
Advertisement